Alteration of plasma von Willebrand factor in the treatment of retinal vein occlusion with cystoid macular edema

Hiromasa Hirai, Mariko Yamashita, Masanori Matsumoto, Takeyuki Nishiyama, Daishi Wada, Naoko Okabe, Yutaro Mizusawa, Hironobu Jimura, Tetsuo Ueda, Nahoko Ogata

1 Department of Ophthalmology, Nara Medical University, Kashihara, Japan, 2 Department of Ophthalmology, Nara City Hospital, Nara, Japan, 3 Department of Blood Transfusion Medicine, Nara Medical University, Kashihara, Japan

* ogata@naramed-u.ac.jp

Abstract

Retinal vein occlusion (RVO) is a major retinal disease caused by venous thrombosis. Although several studies have proposed an association between venous thrombosis and von Willebrand factor (VWF), the association between RVO and VWF remains unclear. We aimed to investigate the association between RVO and VWF and the alteration of VWF levels under anti-vascular endothelial growth factor (VEGF) treatment. We enrolled 55 patients with RVO involved cystoid macular edema. They received intravitreal injection of anti-VEGF drugs, either ranibizumab or aflibercept. We examined the clinical data and measured plasma VWF antigen and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity to identify variabilities during treatment. At baseline, there was no significant difference between the RVO group and age-matched controls in both VWF antigen and ADAMTS13 activity levels, but ADAMTS13 activity was significantly lower in central RVO than in branch RVO ($P = 0.015$). In branch RVO, VWF antigen was negatively correlated with central choroidal thickness ($r = -0.51, P < 0.001$). In branch RVO after anti-VEGF treatment, VWF antigen levels decreased significantly from 134% at baseline to 109% at 1 day ($P = 0.002$) and 107% at 1 month ($P = 0.030$) after treatment. In contrast, ADAMTS13 activity showed no significant difference during this period. In branch RVO at 1 month after treatment, VWF antigen was negatively correlated with central choroidal thickness ($r = -0.47, P = 0.001$). Our findings suggest an association between VWF and central choroidal thickness in patients with branch RVO, thus the measurement of VWF may be useful for evaluating disease activity and prognosis.

Introduction

Von Willebrand factor (VWF), a large glycoprotein synthesized and secreted from vascular endothelial cells, acts as a bridging molecule to adhere platelets to injured vessels and stabilize coagulation factor VIII [1]. VWF is specifically cleaved by disintegrin and metalloproteinase
with a thrombospondin type 1 motif, member 13 (ADAMTS13) [2]. The balance between VWF and ADAMTS13 maintains the hemostatic coagulation function of the whole body. The release of VWF increases with endothelial cell damage, and elevated plasma VWF levels are usually observed in patients with hypertension and atherosclerosis [3–5]. Karaca et al. reported an association between plasma VWF and the severity of hypertensive retinopathy [6]. In other ocular diseases, elevated plasma VWF antigen levels have been reported in age-related macular degeneration, and multimeric VWF has been found in pachychoroid neovasculopathy [7–9]. Several studies have also reported that increased plasma VWF levels are associated with thrombotic complications [10–12]. This association includes not only atherothrombotic diseases (myocardial infarction or ischemic stroke) but also venous thrombosis. Edvardsen et al. recently suggested an association between VWF and venous thrombosis, including deep vein thrombosis and pulmonary embolism [12].

Retinal vein occlusion (RVO) is a major retinal disease that causes retinal hemorrhage and severe vision loss [13,14]. Vision loss in RVO is mainly due to cystoid macular edema. RVO is a multifactorial disease with several risk factors, including age, hypertension, arteriosclerosis, diabetes mellitus, dyslipidemia, high blood viscosity, and thrombosis [14,15]. RVO can be classified into two types: branch RVO and central RVO. In branch RVO, although partial retinal ischemia may occur, blood perfusion throughout the retina is generally maintained [16]. Alternatively, the entire retina can become severely ischemic in central RVO, leading to severe vision loss and neovascular glaucoma [17]. Central RVO usually has a worse prognosis than branch RVO. In patients with RVO, understanding the retinal circulatory status is important for controlling the disease.

Intravitreal injection of anti-vascular endothelial growth factor (VEGF) drugs has been widely used for the treatment of RVO with cystoid macular edema. However, cystoid macular edema often recurs and requires additional injections. The systemic side effects of anti-VEGF vitreous injection remain controversial. Several studies have reported thromboembolic events, including myocardial infarction and ischemic stroke [18,19]. In addition, anti-VEGF antibodies enter the systemic circulation, decrease VEGF levels, and affect other cytokines in the plasma [20]. Previously, we demonstrated that VWF antigen levels decreased after intravitreal aflibercept injection in patients with age-related macular degeneration [8]. Although RVO is caused by venous thrombosis, few clinical studies have examined the association between VWF and RVO; and these studies have reported different results. Thus, the levels of VWF in RVO remain controversial [21–23]. Furthermore, no study has investigated whether plasma VWF is influenced by anti-VEGF vitreous injection in patients with RVO. In this study, we aimed to investigate the involvement of VWF in the pathogenesis of RVO and its variability after anti-VEGF injection.

**Methods**

This prospective study was conducted at Nara Medical University Hospital, Kashihara City, Nara Prefecture, Japan from June 2014 to March 2020. The study protocol was approved by the Medical Research Ethics Committee of Nara Medical University and followed the Declaration of Helsinki. We confirmed that all methods were performed in accordance with the relevant guidelines and regulations. All patients provided written informed consent for participation in the study. We included consecutive patients who provided consent within the research period approved by the Ethics Committee. Finally, we enrolled 55 patients diagnosed with RVO with cystoid macular edema between the ages of 51 and 91 years and 96 age-matched controls (patients before cataract surgery). Patients who had severe systemic complications or who did not receive anti-VEGF drugs, i.e., selected other treatments, were excluded.
RVO was diagnosed based on ophthalmological findings, slit lamp examination, fundus examination, optical coherence tomography, wide-angle fundus photography, and fluorescein angiography. We also examined best-corrected visual acuity (BCVA, LogMAR unit), central retinal thickness (CRT), and central choroidal thickness (CCT). The pathological classification (branch RVO or central RVO) was judged independently by two researchers based on the examinations.

All patients received intravitreal injections of anti-VEGF drugs, either ranibizumab (Lucentis; Novartis International AG, Basel, Switzerland) or aflibercept (Eylea; Bayer HealthCare Pharmaceuticals, Berlin, Germany) at a dose of 2.0 mg/0.05 mL. The drugs were selected by the attending physicians. The intravitreal injection was administered 3.5–4.0 mm posterior to the corneal limbus.

Whole blood was collected by venipuncture of the anterior arm into a tube containing 3.8% trisodium citrate (1:9). Blood samples were collected four times: before treatment (first visit), 1 day after treatment, 1 week after treatment, and 1 month after treatment. All plasma samples were stored at \(-80^\circ C\) and thawed at \(37^\circ C\) prior to examination.

Plasma VWF antigen levels were measured by sandwich enzyme-linked immunosorbent assay (ELISA) using a rabbit anti-human VWF polyclonal antiserum (DAKO, Glostrup, Denmark) [24]; plasma ADAMTS13 activity, by chromogenic ADAMTS13 activity ELISA (Kainos, Tokyo, Japan) [25]. We defined the 100% reference value as the amount of VWF antigen and ADAMTS13 activity in pooled normal plasma from 20 volunteers (10 men and 10 women) aged between 20 and 40 years.

All statistical analyses were performed using EZR (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria) [26]. We used T-tests to compare two continuous variables (such as age) and Fisher’s exact test to compare the proportions of categorical variables (such as sex) between the groups. We also used the Friedman and Wilcoxon signed-rank tests to compare the four continuous variables (VWF antigen). Correlations were evaluated using Pearson’s correlation coefficient. The threshold for significance was set at \(P < 0.05\).

**Results**

The characteristics of the patients with RVO and controls are summarized in Table 1. In patients with RVO, the median age was 73.0 years, and 33 (60%) were male. Twenty-seven patients (49%) had hypertension and twenty-one (38%) had smoking experience. There was no significant difference in VWF antigen and ADAMTS13 activity between the RVO group and the controls (\(P = 0.70\) and \(P = 0.22\), respectively). We also examined the baseline characteristics of patients with RVO classified according to RVO type (branch RVO and central RVO). Both CRT and CCT were significantly thicker in central RVO than in branch RVO (\(P = 0.013\) and \(P = 0.045\), respectively). The number of dyslipidemia cases was also significantly higher in central RVO than in branch RVO (\(P = 0.004\)). Although VWF antigen was not significant between the two groups (\(P = 0.18\), ADAMTS13 activity was significantly lower in central RVO than in branch RVO (\(P = 0.015\)). In other categories, there were no significant differences between the two groups.

We also assessed the blood type because blood type O has the lowest plasma VWF antigen levels [27]. However, there was no difference in blood type between the two groups.

Fig 1 shows the correlation between VWF antigen and each parameter at baseline. In branch RVO, VWF antigen was positively correlated with CRT (\(r = 0.30, P = 0.049\)) but negatively correlated with CCT (\(r = -0.51, P < 0.001\)). In central RVO, no correlations were found in any of the categories.
Table 2 shows the basic characteristics of patients with RVO classified according to the selected anti-VEGF drugs. There were no significant differences between the two groups.

Table 3 shows the alterations of clinical data in patients with RVO by treatment. In total RVO, BCVA significantly improved from 0.40 at baseline to 0.22 at 1 month after anti-VEGF treatment ($P < 0.001$). Both CRT and CCT were significantly thinner at 1 month after treatment ($P < 0.001$ and $P < 0.001$, respectively). In branch RVO, BCVA also significantly improved from 0.35 at baseline to 0.15 at 1 month after treatment ($P < 0.001$). Both CRT and CCT were significantly thinner at 1 month after treatment ($P < 0.001$ and $P = 0.003$, respectively). In central RVO, BCVA significantly improved from 0.40 at baseline to 0.35 at 1 month after treatment ($P = 0.004$). CRT was significantly thinner at 1 month after treatment ($P < 0.001$), whereas CCT was not significant ($P = 0.24$).

Fig 2 shows the correlation between VWF antigen and each parameter at 1 month after anti-VEGF treatment. In branch RVO, VWF antigen was negatively correlated with CCT ($r = -0.47$, $P = 0.001$). In central RVO, no correlations were found in any of the categories.

Fig 3 shows the correlation between VWF antigen and the CCT of fellow eyes at baseline. Five eyes were excluded owing to previous ocular disease. VWF antigen was negatively correlated with CCT ($r = -0.41$, $P = 0.010$) in branch RVO ($n = 39$) but positively correlated with CCT ($r = 0.62$, $P = 0.043$) in central RVO ($n = 11$).

Fig 4 shows the correlation between VWF antigen and the CCT of fellow eyes at 1 month after anti-VEGF treatment. In branch RVO, VWF antigen was negatively correlated with CCT ($r = -0.48$, $P = 0.002$). In central RVO, there was no significant correlation.

Table 1. Basic characteristics of RVO patients and controls.

|                          | Total RVO (n = 55) | Control (n = 96) | $P$ value | Branch RVO (n = 43) | Central RVO (n = 12) | $P$ value |
|--------------------------|-------------------|-----------------|-----------|---------------------|----------------------|-----------|
| Age, median (IQR)        | 73.0 (63.0–79.0)  | 74.0 (69.0–80.0) | 0.18†     | 73.0 (66.0–79.5)    | 72.0 (64.0–74.3)    | 0.33†     |
| Sex (male), n (%)        | 33 (60)           | 52 (54)         | 0.50‡     | 23 (53)             | 10 (83)              | 0.10‡     |
| BCVA, median (IQR), μm   | 0.40 (0.15–0.52)  | -               | 0.30 (0.15–0.52) | 0.40 (0.28–0.57)    | 0.19†     |
| CRT, median (μm)         | 477 (357–614)     | -               | 440 (383–586) | 574 (491–747)       | 0.013†    |
| CCT, median (μm)         | 238 (197–264)     | -               | 235 (180–259) | 257 (214–298)       | 0.045†    |
| Hypertension, n (%)      | 27 (49)           | -               | 20 (47)   | 7 (58)              | 0.53†     |
| Dyslipidemia, n (%)      | 13 (24)           | -               | 6 (14)    | 7 (58)              | 0.004‡    |
| Diabetes, n (%)          | 6 (11)            | -               | 4 (9)     | 2 (17)              | 0.60‡     |
| Cardiovascular disease, n (%) | 8 (15)       | -               | 6 (14)    | 2 (17)              | 1‡        |

Smoking status, n (%)

|                  | Past or Current | Never | Unknown | VWF (%), median (IQR) | ADAMTS13 (%), median (IQR) | Blood Type, n (%) |
|------------------|-----------------|-------|---------|-----------------------|---------------------------|------------------|
| Total RVO (n = 55) | 21 (38)         | 22 (40) | 12 (22) | 134 (92–173)          | 45 (33–61)                | Type O           |
| Control (n = 96)  | 29 (30)         | 67 (70) | 0 (0)   | 130 (109–167)         | 54 (45–63)                | Type A           |
| P value           | 0.37†           | -      | -       | 0.70‡                  | 0.22 †                    | 1§               |
| Branch RVO (n = 43) | 17 (40)         | 17 (40) | 9 (21)  | 139 (107–175)         | 51 (38–69)                | 12 (28)          |
| Central RVO (n = 12) | 4 (33)          | 5 (42)  | 3 (25)  | 92 (60–122)           | 34 (29–39)                | 6 (50)           |
| P value           | 0.75‡           | -      | -       | 0.18†                  | 0.015†                    | 0.18‡            |
| Type O            | 18 (33)         | 32 (33) | -       | 12 (28)               | 6 (50)                   | 0.13†            |
| Type A            | 23 (42)         | 34 (35) | -       | 19 (44)               | 4 (33)                   | 0.74†            |
| Type B            | 9 (16)          | 16 (17) | -       | 9 (21)                | 0 (0)                    | 0.18§            |
| Type AB           | 5 (9)           | 14 (15) | -       | 3 (7)                 | 2 (17)                   | 0.30§            |
| Blood Type, n (%) |                 |        |         |                       |                          |                  |
| Type O            | 18 (33)         | 32 (33) | -       | 12 (28)               | 6 (50)                   | 0.13†            |
| Type A            | 23 (42)         | 34 (35) | -       | 19 (44)               | 4 (33)                   | 0.74†            |
| Type B            | 9 (16)          | 16 (17) | -       | 9 (21)                | 0 (0)                    | 0.18§            |
| Type AB           | 5 (9)           | 14 (15) | -       | 3 (7)                 | 2 (17)                   | 0.30§            |

Abbreviations: RVO, retinal vein occlusion; IQR, interquartile range; BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; VWF, von Willebrand factor.

†T-test.
‡Fisher’s exact test.

https://doi.org/10.1371/journal.pone.0264809.t001
Fig 5 shows the time course of VWF antigen in patients with total RVO, branch RVO, and central RVO. In total RVO, VWF antigen decreased significantly from 134% at baseline to 104% at 1 day after treatment (\( P = 0.002 \)). In branch RVO, VWF antigen also showed a significant reduction from 139% at baseline to 113% at 1 day (\( P = 0.002 \)) and 98% at 1 month (\( P = 0.030 \)) after treatment. However, in central RVO, VWF antigen was not significant during this period. ADAMTS13 activity was not significant during the study period in all categories.

Fig 6 shows the time course of VWF antigen in patients with branch RVO according to the administered drug (ranibizumab or aflibercept). In the ranibizumab group (\( n = 22 \)), VWF

| Table 2. Basic characteristics of patients with RVO classified according to anti-VEGF drugs. |
|-----------------------------------------------|-------------------|-------------------|---|
|                                               | Aflibercept       | Ranibizumab       | \( P \) value |
| Age, median (IQR)                             | 74.0 (66.0–79.0)  | 72.0 (63.5–78.0)  | 0.78 \(^*\) |
| Sex (male), n (%)                             | 15 (54)           | 18 (67)           | 0.41 \(^*\) |
| RVO type (Branch RVO / Central RVO)           | 21 / 7            | 22 / 5            | 0.75 \(^*\) |
| BCVA, median (IQR)                            | 0.22 (0.14–0.52)  | 0.39 (0.26–0.61)  | 0.17 \(^*\) |
| CRT (μm), (IQR)                               | 456 (358–626)     | 481 (371–586)     | 1 \(^*\) |
| CCT (μm), (IQR)                               | 233 (199–257)     | 251 (187–278)     | 0.58 \(^*\) |
| VWF (%), median (IQR)                         | 118 (82–164)      | 139 (111–183)     | 0.54 \(^*\) |
| ADAMTS13 (%), median (IQR)                    | 40 (31–53)        | 51 (34–69)        | 0.67 \(^*\) |

Abbreviations: IQR, interquartile range; BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; VWF, von Willebrand factor; RVO, retinal vein occlusion.

\(^*\) T-test.

\(^*\) Fisher’s exact test.
antigen decreased significantly from 145% at baseline to 122% at 1 day after treatment (P < 0.001). However, VWF antigen was not different in the aflibercept group (n = 21).

Discussion

This study investigated the coagulation-related factors in patients with RVO at baseline and their alterations during treatment. According to our results, plasma VWF was not significant between the RVO group and age-matched controls at baseline. Several researchers have reported that plasma VWF increases not only in patients with hypertension and arteriosclerosis but also in healthy individuals with aging [28,29].

Table 3. Alterations of clinical data in patients with RVO by treatment.

|                      | Total RVO (n = 55) | P value | Branch RVO (n = 43) | P value | Central RVO (n = 12) | P value |
|----------------------|--------------------|---------|---------------------|---------|----------------------|---------|
|                      | Baseline           | 1 month | Baseline            | 1 month | Baseline             | 1 month |
| BCVA, median [IQR]   | 0.40 (0.15–0.52)   | 0.22    | 0.35 (0.15–0.52)   | 0.15    | 0.35 (0.21–0.40)    | 0.040   |
| CRT (μm), median [IQR]| 477 (357–614)      | 224     | 440 (343–586)       | 222     | 574 (491–747)       | 0.001†  |
| CCT (μm), median [IQR]| 238 (197–264)      | 215     | 235 (180–259)       | 213     | 257 (214–298)       | 0.003†  |

Abbreviations: IQR, interquartile range; BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; RVO, retinal vein occlusion.

† Paired T-test.

https://doi.org/10.1371/journal.pone.0264809.t003

Fig 2. Correlations between VWF antigen and parameters (BCVA, CRT, and CCT) at 1 month after anti-VEGF treatment. In each graph, the horizontal axis presents the VWF antigen (%). BCVA, best-corrected visual acuity (LogMAR unit); CRT, central retinal thickness; CCT, central choroidal thickness; RVO, retinal vein occlusion.

https://doi.org/10.1371/journal.pone.0264809.g002
ADAMTS13 activity was significantly lower in central RVO than in branch RVO at baseline, but the number of dyslipidemia cases was significantly higher in central RVO. ADAMTS13 is mainly synthesized in hepatic stellate cells [2]. Thus, the liver cells in patients with dyslipidemia could be damaged by fat deposition, and production of ADAMTS13 could be decreased in patients with central RVO.

Although it was not significant, the VWF levels in branch RVO were higher than those in central RVO. Branch RVO is caused by a thrombus at the arteriovenous crossing point, where the retinal artery and vein share an outer sheath [30,31]; therefore, the arterial pressure is a direct cause of thrombosis. However, central RVO is caused by a thrombus in the central retinal vein, where it passes through the lamina cribrosa within the optic nerve. A recent study

---

*Fig 3. The correlation between VWF antigen and the CCT of fellow eyes at baseline. CCT, central choroidal thickness; RVO, retinal vein occlusion.*

[https://doi.org/10.1371/journal.pone.0264809.g003](https://doi.org/10.1371/journal.pone.0264809.g003)

*Fig 4. The correlation between VWF antigen and the CCT of fellow eyes at 1 month after anti-VEGF treatment. CCT, central choroidal thickness; RVO, retinal vein occlusion.*

[https://doi.org/10.1371/journal.pone.0264809.g004](https://doi.org/10.1371/journal.pone.0264809.g004)
focusing on branch and central RVO has shown that atherosclerosis is more likely to lead to the development of branch RVO than central RVO [32]. The high levels of plasma VWF in our study suggest atherosclerosis in branch RVO.

We also compared VWF levels with each of the ophthalmologic parameters of RVO and found that VWF antigen was negatively correlated with CCT in branch RVO at baseline. This association between VWF antigen and CCT was also observed in fellow eyes, suggesting systemic VWF levels may affect choroidal circulation in patients with branch RVO. In contrast, VWF antigen was not significantly correlated with CCT in the affected eyes of patients with central RVO before or after treatment. These differences in results may suggest pathological differences between central and branch RVO. Moreover, central RVO has been reported to be accompanied by decreased ocular circulation and intense congestion [17], which may have...
influenced the association between VWF and choroidal thickness. The choroid, consisting of microcapillaries, and its structure can be observed noninvasively using optical coherence tomography. Several researchers have recently focused on the choroid as an indicator of systemic microcirculation [33,34], but the biochemical factors affecting the choroidal structure have not been well investigated. The studies examining the association between VWF and choroidal thickness are few; only Gifford et al. reported an inverse association between choroidal thickness and VWF in patients with liver cirrhosis [34].

Many previous reports demonstrated that choroidal thickness in patients with RVO decreases after intravitreal injection of anti-VEGF drugs [35]. Sakanishi et al. reported that the recurrence of cystoid macular edema was significantly low in cases with choroidal thinning after treatment [36]. Thus, CCT may reflect the treatment effect and prognosis in RVO. Moreover, VWF antigen was negatively correlated with CCT even at 1 month after anti-VEGF injection in branch RVO. The measurement of VWF antigen during treatment may be useful in evaluating the disease activity of branch RVO. VWF antigen also showed significant alterations under anti-VEGF treatment, especially in the ranibizumab group in branch RVO. Several researchers have previously proposed an association between VWF and VEGF [37,38].

VWF is secreted from endothelial-specific organelles called Weibel–Palade bodies that widely distribute it in systemic vessels [2]. VEGF activates exocytosis of Weibel–Palade bodies, resulting in the secretion of VWF, which activates VEGF-R2 signaling and regulates angiogenesis [39].

Pace et al. have recently reported decreased VWF plasma levels after anti-VEGF treatment (bevacizumab) in recurrent glioma [40]. This result was obtained with a relatively high dose (10 mg/kg) of the anti-VEGF drug administered intravenously. In the present study, we showed that plasma VWF concentrations can be altered even with small intravitreal doses (0.05 mL). The VWF levels in patients with branch RVO was significantly decreased in the ranibizumab group but not in the aflibercept group. Aflibercept is a recombinant protein composed of VEGF-R1 and 2 bound to the IgG-1 Fc portion. In contrast, ranibizumab is a monoclonal antibody fragment that inhibits the active isoform of VEGF-A [41]. The structural variations between aflibercept and ranibizumab may have resulted in the differences in release of VWF into the plasma via VEGF-R2.

This study has some limitations. First, this was a cross-sectional study with a relatively small sample size. A larger number of patients will be required for more reliable analyses. Second, we only assessed patients who received anti-VEGF drugs. It might be necessary to compare VWF levels in patients with and without treatment during the same time course. However, it is difficult to analyze untreated patients through frequent medical visits. Finally, we did not evaluate the long-term effects of anti-VEGF drugs for more than 1 month after intravitreal injection. A longer follow-up period is required to confirm these results.

**Conclusion**

We performed prospective analyses of VWF in patients with RVO during treatment and found unique characteristics. Our findings suggest an association between VWF and CCT in branch RVO; thus, the measurement of VWF may be useful in evaluating disease activity and prognosis.

**Acknowledgments**

The authors thank Hiroki Tsujinaka for his useful discussions and Editage (www.editage.com) for English language editing.
Author Contributions

Conceptualization: Masanori Matsumoto, Tetsuo Ueda, Nahoko Ogata.

Data curation: Hiromasa Hirai, Mariko Yamashita.

Formal analysis: Hiromasa Hirai, Mariko Yamashita.

Investigation: Hiromasa Hirai, Mariko Yamashita.

Methodology: Masanori Matsumoto.

Project administration: Nahoko Ogata.

Resources: Hiromasa Hirai, Masanori Matsumoto, Takeyuki Nishiyama, Daishi Wada, Naoko Okabe, Yutaro Mizusawa, Hironobu Jimura, Nahoko Ogata.

Supervision: Nahoko Ogata.

Validation: Hiromasa Hirai, Mariko Yamashita.

Visualization: Hiromasa Hirai.

Writing – original draft: Hiromasa Hirai.

Writing – review & editing: Masanori Matsumoto, Tetsuo Ueda, Nahoko Ogata.

References

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998; 67: 395–424. https://doi.org/10.1146/annurev.biochem.67.1.395 PMID: 9759493

2. Crawley JT, de Groot R, Xiang Y, Luken BM, Lane DA. Unraveling the scissile bond: how ADAMTS13 recognizes and cleaves von Willebrand factor. Blood. 2011; 118: 3212–3221. https://doi.org/10.1182/blood-2011-02-30697 PMID: 21715308

3. Blann AD, Naqvi T, Waite M, McCollum CN. von Willebrand factor and endothelial damage in essential hypertension. J Hum Hypertens. 1993; 7: 107–111. PMID: 8510081

4. Blann AD, McCollum CN. von Willebrand factor, endothelial cell damage and atherosclerosis. Eur J Vasc Surg. 1994; 8: 10–15. https://doi.org/10.1016/s0950-821 x(05)80112-4 PMID: 8307205

5. Lip GY, Blann A. von Willebrand factor: a marker of endothelial dysfunction in vascular disorders. Cardiovasc Res. 1997; 34: 255–265. https://doi.org/10.1016/s0008-6363(97)00394-9 PMID: 9205537

6. Karaca M, Coban E, Ozdem S, Unal M, Salim O, Yucel O. The association between endothelial dys-function and hypertensive retinopathy in essential hypertension. Med Sci Monit. 2014; 20: 78–82. https://doi.org/10.12659/MSM.889659 PMID: 24441931

7. Lip PL, Blann AD, Hope-Ross M, Gibson JM, Lip GY. Age-related macular degeneration is associated with increased vascular endothelial growth factor, hemorheology and endothelial dysfunction. Ophthalmology. 2001; 108: 705–710. https://doi.org/10.1016/s0161-6420(00)00663-1 PMID: 11297487

8. Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Fujimura Y, Ogata N. Intravitreal injection of aflibercept, an anti-VEGF antagonist, down-regulates plasma von Willebrand factor in patients with age-related macular degeneration. Sci Rep. 2018; 8: 1491. https://doi.org/10.1038/s41598-018-19473-0 PMID: 29367644

9. Hirai H, Yamashita M, Matsumoto M, Hayakawa M, Sakai K, Ueda T, et al. Analysis focusing on plasma von Willebrand factor in pachychoroid neovascularopathy and age-related macular degeneration. Sci Rep. 2021; 11: 19987. https://doi.org/10.1038/s41598-021-99557-6 PMID: 34620972

10. Buchtele N, Schwameis M, Gilbert JC, Schörgenhofer C, Jilma B. Targeting von Willebrand Factor in ischaemic stroke: focus on clinical evidence. Thromb Haemost. 2018; 118: 959–978. https://doi.org/10.1055/s-0038-1648251 PMID: 29847840

11. Spiel AO, Gilbert JC, Jilma B. von Willebrand factor in cardiovascular disease: focus on acute coronary syndromes. Circulation. 2008; 117: 1449–1459. https://doi.org/10.1161/CIRCULATIONAHA.107.722827 PMID: 18347221

12. Edvardsen MS, Hindberg K, Hansen ES, Morelli VM, Ueland T, Aukrust P, et al. Plasma levels of von Willebrand factor and future risk of incident venous thromboembolism. Blood Adv. 2021; 5: 224–232. https://doi.org/10.1182/bloodadvances.2020003135 PMID: 33570640
13. Li J, Paulus YM, Shuai Y, Fang W, Liu Q, Yuan S. New developments in the classification, pathogenesis, risk factors, natural history, and treatment of branch retinal vein occlusion. J Ophthalmol. 2017; 2017: 4936924. https://doi.org/10.1155/2017/4936924 PMID: 28386476

14. Yasuda M, Kyohara Y, Arakawa S, Hata Y, Yonemoto K, Doi Y, et al. Prevalence and systemic risk factors for retinal vein occlusion in a general Japanese population: the Hisayama study. Invest Ophthalmol Vis Sci. 2010; 51: 3205–3209. https://doi.org/10.1167/iovs.09-4453 PMID: 20071683

15. Kolar P. Risk factors for central and branch retinal vein occlusion: a meta-analysis of published clinical data. J Ophthalmol. 2014; 2014: 724780. https://doi.org/10.1155/2014/724780 PMID: 25009743

16. Hamid S, Mirza SA, Shokh I. Branch retinal vein occlusion. J Ayub Med Coll Abbottabad. 2008; 20: 128–132.

17. Bradshaw SE, Gala S, Nanavaty M, Shah A, Mwamburi M, Kefalas P. Systematic literature review of treatments for management of complications of ischemic central retinal vein occlusion. BMC Ophthalmol. 2016; 16: 104. https://doi.org/10.1186/s12886-016-0282-5 PMID: 25009743

18. Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond). 2013; 27: 787–794. https://doi.org/10.1038/eye.2013.107 PMID: 23722722

19. Porta M, Striglia E. Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med. 2020; 15: 199–210. https://doi.org/10.1007/s11739-019-02253-7 PMID: 31848994

20. Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T. Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol. 2010; 94: 1215–1218. https://doi.org/10.1136/bjo.2008.156810 PMID: 20538658

21. Cortinovis A, Crippa A, Crippa M. [Factor VIII/Ag (von Willebrand) and protein C. Erythrocyte deformability and aggregability. The risk parameters of retinal vein occlusion]. Minerva Med. 1994; 85: 211–219.

22. Lip PL, Blann AD, Jones AF, Lip GY. Abnormalities in haemorheological factors and lipoprotein (a) in retinal vascular occlusion: implications for increased vascular risk. Eye (Lond). 1998; 12: 245–251. https://doi.org/10.1038/eye.1998.58 PMID: 9683948

23. Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001; 85: 1313–1315. https://doi.org/10.1136/bjo.85.11.1313 PMID: 11673296

24. Matsumoto M, Kawaguchi S, Ishizashi H, Yagi H, Iida J, Sakaki T, et al. Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. Pathophysiol Haemost Thromb. 2005; 34: 35–40. https://doi.org/10.1159/00008546 PMID: 16293984

25. Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006; 46: 1444–1452. https://doi.org/10.1111/j.1537-2995.2006.00914.x PMID: 16934083

26. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48: 452–458. https://doi.org/10.1038/bmt.2012.244 PMID: 23208313

27. Gallinano L, Cattini MG, Sztukowski M, Padrini R, Santorelli F, Pontara E, et al. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood. 2008; 111: 3540–3545. https://doi.org/10.1182/blood-2007-11-122945 PMID: 18245665

28. Alavi P, Rathod AM, Jahroudi N. Age-Associated Increase in Thrombogenicity and Its Correlation with von Willebrand Factor. J Clin Med. 2021; 10: 4190. https://doi.org/10.3390/jcm10184190 PMID: 34575297

29. Biguzzi E, Castelli F, Lijfering WM, Cannegieter SC, Eikenboom J, Rosendaal FR, et al. Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors. Thromb Res. 2021; 197: 172–178. https://doi.org/10.1016/j.thromres.2020.11.016 PMID: 33221577

30. Hawkins WR. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol. 1990; 110: 97–98. https://doi.org/10.1016/s0002-9394(91)76593-3 PMID: 2386833

31. Frangieh GT, Green WR, Barrakuer-Somers E, Finkelstein D. Histopathologic study of nine branch retinal vein occlusions. Arch Ophthalmol. 1982; 100: 1132–1140. https://doi.org/10.1001/archophthalm.1982.01030040110020 PMID: 6178389

32. Lyu M, Lee Y, Kim BS, Kim HJ, Hong R, Shin YU, et al. Clinical significance of subclinical atherosclerosis in retinal vein occlusion. Sci Rep. 2021; 11: 11905. https://doi.org/10.1038/s41598-021-91401-1 PMID: 34099806
33. Balmforth C, van Bragt JJ, Ruijs T, Cameron JR, Kimmitt R, Moorhouse R, et al. Chorioretinal thinning in chronic kidney disease links to inflammation and endothelial dysfunction. JCI Insight. 2016; 1: e89173. https://doi.org/10.1172/jci.insight.89173 PMID: 27942587

34. Gifford FJ, Moroni F, Farrah TE, Hetherington K, MacGillivray TJ, Hayes PC, et al. The eye as a non-invasive window to the microcirculation in liver cirrhosis: a prospective pilot study. J Clin Med. 2020; 9: E3332. https://doi.org/10.3390/jcm9103332 PMID: 33080821

35. Kim KH, Lee DH, Lee JJ, Park SW, Byon IS, Lee JE. Regional choroidal thickness changes in branch retinal vein occlusion with macular edema. Ophthalmologica. 2015; 234: 109–118. https://doi.org/10.1159/000437276 PMID: 26305536

36. Sakanishi Y, Morita S, Mashimo K, Tamaki K, Ebihara N. Subfoveal choroidal thickness and treatment outcomes of intravitreal aflibercept for branch retinal vein occlusion. Life (Basel). 2021; 11: 572. https://doi.org/10.3390/life11060572 PMID: 34204557

37. Ishihara J, Ishihara A, Starke RD, Peghaire CR, Smith KE, McKinnon TAJ, et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. Blood. 2019; 133: 2559–2569. https://doi.org/10.1182/blood.2019000510 PMID: 30975637

38. Rondaij MG, Bierings R, Kragt A, van Mourik JA, Voorberg J. Dynamics and plasticity of Weibel-Palade bodies in endothelial cells. Arterioscler Thromb Vasc Biol. 2006; 26: 1002–1007. https://doi.org/10.1161/01.ATV.0000209501.56852.6c PMID: 16469951

39. Randi AM. Endothelial dysfunction in von Willebrand disease: angiogenesis and angiodyplasia. Thromb Res. 2016; 141 Suppl 2: S55–S58. https://doi.org/10.1016/S0049-3848(16)30366-8 PMID: 27207426

40. Pace A, Mandoj C, Antenucci A, Villani V, Sperduti I, Casini B, et al. A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma. J Neurooncol. 2018; 138: 527–535. https://doi.org/10.1007/s11060-018-2820-x PMID: 29594657

41. Howaidy A, Eldaly ZH. Comparison of structural and functional outcome of aflibercept versus ranibizumab in patients with myopic choroidal neovascularization. Eur J Ophthalmol. 2021; 31: 211–217. https://doi.org/10.1177/1120672119883590 PMID: 31690105